---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-023971"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T12:59:34.179182+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Daré Bioscience Q2 2025: Cash $5.0M, Sildenafil Cream launch on track for Q4 2025, Ovaprene DSMB positive

## Summary
- Cash of $5.0M at June 30; working capital deficit $12.6M; raised ~$17.6M net from ATM and $6M grant post-quarter.
- G&A $2.4M, R&D $1.4M (down 71% YoY) reflecting increased contra R&D from grants.
- DARE to PLAY Sildenafil Cream on track for Q4 2025 launch via 503B compounding, targeting near-term revenue.
- Ovaprene Phase 3 DSMB recommended continuation no new safety concerns; interim pregnancy rate consistent.
- DARE-HRT1 monthly ring pursuing 503B compounding for late 2026 alongside FDA pathway.

## SEC filing metadata
- accession: 0001641172-25-023971
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000164117225023971/0001641172-25-023971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000164117225023971/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-023971
- JSON: https://secwatch.observer/filing/0001641172-25-023971.json
- Plain text: https://secwatch.observer/filing/0001641172-25-023971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.